New Spravato FDA Approval Opens The Door to New Patients, Says Sandhya Prashad, M.D.
Sandhya Prashad, MD
August 3, 2020
A new indication of Janssen’s ketamine based-nasal spray Spravato (intranasal esketamine) has been approved for rapid reduction of depression symptoms